Molecular insights in HIV-associated cardiac dysfunction Authors: María Valero-Muñoz, Eng Leng Saw, David R. Pimentel, Adam C. Gower, Suman Srinivasa, Markella V. Zanni, Mabel Toribio, Steven K. Grinspoon, Flora Sam Published: 2025 ABSTRACT BackgroundAntiretroviral therapy (ART) in human immunodeficiency virus (HIV) markedly improved life expectancy in persons living with HIV (PLWH), but cardiac disease has emerged as the leading cause of death in this population. The prevalence of impaired diastolic function and heart failure with preserved ejection fraction (HFpEF) is higher among PLWH on ART. However, the specific role that HIV itself, and/or ART may have on the cardiomyocyte phenotype is unknown. We investigated modified molecular pathways in cardiomyocytes after exposure to serum from the same patients who were initially ART-naïve and then subsequently ART-treated.MethodsRat cardiomyocytes were treated for 24 hours with serum obtained longitudinally from PLWH (N = 10) before and after being on ART for 6 months. Transcriptomic changes were determined by RNA sequencing. Measures of apoptosis, calcium handling, and extracellular matrix remodeling were analyzed using TUNEL assay and western blot.ResultsHere we show that exposure to serum from ART-naïve PLWH increases cardiomyocyte cell death. In contrast, exposure to serum obtained from the same PLWH after six months on ART results in altered expression of calcium-handling proteins and upregulation of profibrotic and extracellular matrix–related markers, indicating altered contraction and relaxation, and adverse cardiac remodeling.ConclusionsThese findings demonstrate dysregulated molecular pathways in cardiomyocytes following exposure to untreated HIV serum versus ART-treated HIV serum from patients followed longitudinally. Altogether, these data suggest that HIV infection and ART contribute to changes seen in the cardiomyocyte phenotype and play complementary roles in the pathogenesis of diastolic dysfunction and HFpEF in PLWH. Introduction Human immunodeficiency virus (HIV) infection afflicts more than 39 million people worldwide1. Antiretroviral therapies (ART) have markedly decreased opportunistic infections and increased survival in persons living with HIV (PLWH)2. As such, acquired immunodeficiency syndrome (AIDS)1 in PLWH has evolved from a lethal disease to a multimorbid, complex chronic condition where PLWH without AIDS are at high risk for cardiovascular disease (CVD)3. CVD is the third most common cause of non-AIDS-related death in PLWH, but is the leading cause of death in PLWH on ART4. A recent, large, retrospective, longitudinal cohort study demonstrated that PLWH initiated on integrase strand transfer inhibitor (INSTI)-based ART were at increased risk of developing certain cardiometabolic related-diseases, such as heart failure, myocardial infarction, and lipid disorders, compared with PLWH on non-INSTI-based ART5. However, other studies showed either an early increased CV risk with INSTI initiation, but with subsequent normalization of this risk6, or the absence of both short- or long-term CV risk in PLWH initiated on INSTI-based therapies7,8. Before the implementation of ART, HIV-associated cardiomyopathy was common and PLWH, usually with advanced AIDS, presented with systolic heart failure9 or heart failure with reduced ejection fraction (HFrEF). However, with ART use and suppressed HIV viremia, PLWH now present with another cardiac phenotype i.e., subclinical left ventricular (LV) diastolic dysfunction with heart failure and a normal LV ejection fraction which closely resembles the early stages of heart failure with preserved ejection fraction (HFpEF)10. Despite several clinical studies demonstrating cardiac disease in PLWH, it is unknown if HIV infection itself and/or ART causes the heart failure phenotypes seen in this population, or if heart failure is simply secondary to metabolic dysregulation11–13. Short-term use of ART mediates cardioprotective effects14, but long-term use may trigger negative effects, raising concerns about the adverse effects of ART during the clinical course of heart failure in PLWH15. Given the increasing incidence of heart failure and its associated morbidity in PLWH, there is a need to understand the role of ART in mediating the pathogenesis of heart failure and LV diastolic dysfunction16. Previous studies used retrospective data, cardiac tissue, or cultured cardiomyocytes to investigate direct HIV viral infection, immune activation, or side effects of ART17,18. The HIV does not directly enter cardiomyocytes, as cardiomyocytes lack CD4 receptors, required for direct internalization19. However, it has been suggested that internalization occurs via co-infection with other cardiotropic pathogens20 or by macrophage infiltration in a “Trojan-like” manner, promoting cell death, progression to cardiac dysfunction, and cardiomyopathy with heart failure21,22. Marked cytokine production and an abnormal inflammatory response in PLWH are also posited to play a pathogenic role in HIV-associated heart failure by activating signaling pathways17,18, known to trigger abnormal cardiac remodeling and cellular death in cardiomyocytes23,24. The current study used the serum samples from the completed study by Zanni et al., “Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients with HIV Infection” in JAMA Cardiology25. FDG PET scanning and coronary CT angiography were used to investigated arterial inflammation and subclinical atherosclerosis in PLWH. In addition, systemic immune activation and metabolic biomarkers were measured before and six months after the initiation of combined ART with an integrase inhibitor-based regimen consisting of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate. Despite the reduction of systemic immune activation with combined ART after six months in treatment-naïve PLWH, arterial inflammation persisted, and progression of coronary plaque volume was still seen25. In this ancillary study, we employ a translational approach by treating isolated primary adult rat ventricular cardiomyocytes (ARVMs) with serum from these individuals with newly diagnosed, treatment-naïve HIV infection (i.e., ART-naïve PLWH), and from the same participants six months aftercombination ART obtained from the cohort described by Zanni et al. 25. Using this in vitro model, we identify distinct molecular changes in cardiomyocytes exposed to serum from untreated versus ART-treated individuals, revealing alterations in pathways related to cellular death, calcium-handling proteins, and cardiac structural remodeling. These findings suggest that HIV infection and subsequent ART exposure are associated with a unique cardiomyocyte phenotype that may contribute to the development of cardiac dysfunction and HFpEF in persons living with HIV. Methods Serum Samples Blood samples were obtained from a prior, completed, prospective clinical study investigating the effects of ART on arterial and systemic inflammation in PLWH25. Ten PLWH before treatment (ART-naïve) and 6-months after initiating combination ART consisting of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate were included. These participants were enrolled at the General Clinical Research Center at Massachusetts General Hospital. Ten participants never infected with HIV nor on pre-exposure prophylaxis were recruited from the same community26–28. The detailed inclusion and exclusion criteria were previously reported25–28. Briefly, all participants were at least 18 years old, with no current nor prior coronary arterial disease (CAD), and no autoimmune or inflammatory disease other than HIV. Table 1 summarizes the main clinical characteristics.Table 1Characteristics of the same PLWH followed longitudinally (ART-naïve and 6 months on ART) and persons without HIV (controls)Controls N = 10PLWH before ART N = 10PLWH on ART N = 10P-value before ART vs. on ARTAge, years52 ± 732 ± 10Male Sex, %70100RaceAsian %010Black %2010White %8080BMI, kg/m225.3 ± 3.725.6 ± 4.025.9 ± 3.7NSSystolic Blood Pressure, mmHg120 ± 12114 ± 6116 ± 6NSTotal Cholesterol, mg/dL172 (153, 199)152 (133, 171)154 (146, 189)0.040LDL, mg/dL92 ± 2591 ± 28101 ± 320.050HDL, mg/dL56 (53, 64)40 (37, 47)46 (42, 58)NSTriglycerides, mg/dL111 ± 6784 ± 29102 ± 46NS10-year ASCVD risk score, %3.1 ± 2.72.2 ± 1.8NAType 2 diabetes mellitus, %00NACurrent Statin Use, %100NADuration of HIV, yearsN/A0.8 (0.1, 1.6)NACD4 + T-cell count, cells/μLN/A448 ± 159676 ± 2000.001CD8 + T-cell count, cells/μLN/A789 (635, 1283)939 (644, 1348)NSCD4 + /CD8+ ratioN/A0.54 ± 0.200.79 ± 0.350.003Log HIV Viral Load, copies/mLN/A4.5 (4.4, 4.9)1.3 (1.3, 1.3)0.002Undetectable Viral Load, %N/A0100History of HCV infection, %010Data are reported as mean ± standard deviation (SD) for normally distributed variables. For non-normally distributed variables, data is presented as median and interquartile range (IQR). Categorical variables were reported as percentages. Statistics by paired Student t-test for normally distributed data or Wilcoxon signed rank test for non-distributed data. ART Antiretroviral therapy, ASCVD Atherosclerotic cardiovascular disease, BMI Body mass index, HDL High-density lipoprotein LDL Low-density lipoprotein, NA non-applicable PLWH persons living with HIV. Table 1Characteristics of the same PLWH followed longitudinally (ART-naïve and 6 months on ART) and persons without HIV (controls)Controls N = 10PLWH before ART N = 10PLWH on ART N = 10P-value before ART vs. on ARTAge, years52 ± 732 ± 10Male Sex, %70100RaceAsian %010Black %2010White %8080BMI, kg/m225.3 ± 3.725.6 ± 4.025.9 ± 3.7NSSystolic Blood Pressure, mmHg120 ± 12114 ± 6116 ± 6NSTotal Cholesterol, mg/dL172 (153, 199)152 (133, 171)154 (146, 189)0.040LDL, mg/dL92 ± 2591 ± 28101 ± 320.050HDL, mg/dL56 (53, 64)40 (37, 47)46 (42, 58)NSTriglycerides, mg/dL111 ± 6784 ± 29102 ± 46NS10-year ASCVD risk score, %3.1 ± 2.72.2 ± 1.8NAType 2 diabetes mellitus, %00NACurrent Statin Use, %100NADuration of HIV, yearsN/A0.8 (0.1, 1.6)NACD4 + T-cell count, cells/μLN/A448 ± 159676 ± 2000.001CD8 + T-cell count, cells/μLN/A789 (635, 1283)939 (644, 1348)NSCD4 + /CD8+ ratioN/A0.54 ± 0.200.79 ± 0.350.003Log HIV Viral Load, copies/mLN/A4.5 (4.4, 4.9)1.3 (1.3, 1.3)0.002Undetectable Viral Load, %N/A0100History of HCV infection, %010Data are reported as mean ± standard deviation (SD) for normally distributed variables. For non-normally distributed variables, data is presented as median and interquartile range (IQR). Categorical variables were reported as percentages. Statistics by paired Student t-test for normally distributed data or Wilcoxon signed rank test for non-distributed data. ART Antiretroviral therapy, ASCVD Atherosclerotic cardiovascular disease, BMI Body mass index, HDL High-density lipoprotein LDL Low-density lipoprotein, NA non-applicable PLWH persons living with HIV. Characteristics of the same PLWH followed longitudinally (ART-naïve and 6 months on ART) and persons without HIV (controls) Data are reported as mean ± standard deviation (SD) for normally distributed variables. For non-normally distributed variables, data is presented as median and interquartile range (IQR). Categorical variables were reported as percentages. Statistics by paired Student t-test for normally distributed data or Wilcoxon signed rank test for non-distributed data. ART Antiretroviral therapy, ASCVD Atherosclerotic cardiovascular disease, BMI Body mass index, HDL High-density lipoprotein LDL Low-density lipoprotein, NA non-applicable PLWH persons living with HIV. Ethics The Massachusetts General Hospital IRB approved the use of human serum samples for the study, conducted according to the Declaration of Helsinki principles. Written informed consent was obtained from all subjects before the collection of the samples (IRB# 2012P001138). The use of rats conformed to the Guide for the Care and Use of Laboratory Animals published by the US NIH and was approved by the IACUC at Boston University School of Medicine (IACUC# PROTO201800083). Adult Rat Ventricular Cardiac Myocytes Culture and Treatment Isolation and culture of ARVMs were performed as described previously29–31. Briefly, adult male Sprague-Dawley rats (Envigo, Indianapolis, IN, USA) were euthanized with a single dose of 200 mg/kg of pentobarbital (i.p). After euthanasia, the chest was quickly cleaned and opened, and the heart was removed with sterile instruments, and perfused with enzyme-containing solutions for cell isolation. ARVM (90–95% purity) were then collected and plated non-confluently on laminin-coated (1 µg/cm2) plastic culture dishes. Cells were maintained at 5% CO2 and 37 °C in Dulbecco’s Modified Eagle Medium (DMEM) containing 2 mg/mL bovine serum albumin, 2mmol/L L-carnitine, 5 mmol/L creatinine, 5 mmol/L taurine (Sigma-Aldrich, St. Louis, MO, USA), 100 IU/mL penicillin, and 10 g/mL streptomycin. Laminin, DMEM, penicillin and streptomycin were purchased from Thermo Fisher Scientific (Waltham, MA, USA). ARVMs were divided into three experimental groups based on the source of serum used for treatment: (i) serum from persons with HIV before initiation of antiretroviral therapy (N = 10), (ii) serum from the same individuals after six months on ART (N = 10), and (iii) serum from HIV-negative control subjects (N = 10). Culture medium was supplemented with 10% serum from the respective group for 24 h, after which the serum was removed, and cells were collected for subsequent analyses (Supplementary Fig. 1). To minimize potential confounders, ARVM treatments and measurements were performed in parallel using randomized sample order and similar experimental conditions. Investigators were blinded to group during the conduct of the experiment. Culture wells and processing order were alternated to avoid batch or positional effects. Sample Preparation and RNA Sequencing Total RNA was isolated using RNeasy® plus universal mini kit (Qiagen, Germantown, MD, USA) according to the manufacturer’s instructions. The integrity of total RNA was determined using the High Sensitivity RNA Pico 6000 assay ran on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 100 ng of total RNA were used for mRNA library preparation using the Illumina® Stranded mRNA Library Preparation kit and sequenced on a NextSeq 2000 instrument (Illumina, San Diego, CA, USA). The procedures for mRNA library preparation, RNA Sequencing and the following data analyses were carried out by the Boston University Microarray and Sequencing Resource core facility. RNA Sequencing Analysis FASTQ files were aligned to rat genome build rn7 using STAR (version 2.7.9a)32. Ensembl-Gene-levels counts for non-mitochondrial genes were generated using featureCounts (version 1.6.2) and Ensembl annotation build 109. FASTQ quality was assessed using FastQC (version 0.11.7), and alignment quality was assessed using RSeQC (version 3.0.0). Because cardiomyocytes were obtained from two different animals (obtaining 3 samples per group, per animal for a total N = 6 per group), read counts were corrected for ARVM batch using the ComBat_seq function in the sva R package (version 3.40.0) prior to analysis. Differential expression was then assessed using the likelihood ratio test (LRT) and Wald test implemented in the DESeq2 R package (version 1.23.10)33. A paired Wald test (i.e., correcting for the subject as a covariate) was used when comparing cardiomyocytes treated with matched pairs of serum from the same PLWH both before and 6 months after ART initiation. Correction for multiple hypothesis testing was accomplished using the Benjamini-Hochberg false discovery rate (FDR). Variance-stabilizing transformation (VST) was carried out on batch-corrected counts using the DESeq2 R package. Human homologs of rat genes were identified using the NCBI ‘gene_orthologs’ table (retrieved 2023-05-25). All analyses were performed using the R environment for statistical computing (version 4.1.2). Gene Set Enrichment Analysis Gene Set Enrichment Analysis (GSEA; version 2.2.1)34 was used to identify biological terms, pathways and processes that were coordinately up- or down-regulated within each pairwise comparison. The Entrez Gene identifiers of the human homologs of all genes in the Ensembl Gene annotation were ranked by the Wald statistic computed for each pairwise comparison. Ensembl Genes matching multiple rat Entrez Gene identifiers, and rat genes with multiple human homologs, were excluded prior to ranking, so that the ranked list represents only those human Entrez Gene IDs that match exactly one rat Ensembl Gene. Each ranked list was then used to perform pre-ranked GSEA analyses using the Entrez Gene versions of the H (Hallmark), C2 CP (Biocarta, KEGG, PID, Reactome, WikiPathways), and C5 (Gene Ontology, GO) gene sets obtained from the Molecular Signatures Database (MSigDB), version 7.5.1. In Situ Apoptosis Detection and Cardiomyocyte Size Analysis The detection of fragmented DNA in ARVMs was performed by using a Click-iT Plus TUNEL assay kit according to manufacturer’s instructions. Then, the cells were stained with anti-cardiac troponin T antibody (cTnT; 1:100), followed by anti-mouse IgG1 secondary antibody conjugated to Alexa Fluor™ 568 (1:200) and DAPI (1:1000; Santa Cruz Biotechnology, Dallas, TX, USA). The assay kit, primary and secondary antibodies were purchased from Thermo Fisher Scientific. Immunofluorescent images were captured at 20X using a Keyence BZ-9000 BioRevo microscope (Itasca, IL, USA). Image J (National Institutes of Health) software was used for image analysis. The frequency of apoptosis was expressed as the number of TUNEL+/cTnT+ rod-shaped ARVM per total number of cTnT+ rod-shaped ARVMs. For each sample, we analyzed an average of 484, 1209, and 1174 cardiomyocytes in the “CT”, “Before ART”, and “After ART” groups, respectively. Investigators were blinded to group during data collection. Additionally, images were used to determine cardiomyocyte size. Cross-sectional area was measured using Image J and expressed as the mean area in µm2. An average of 198, 421, and 454 cardiomyocytes in the “CT”, “Before ART”, and “After ART” groups, respectively were analyzed. Gene expression analysis Total RNA was subjected to reverse transcription, pre-amplification, and quantitative polymerase chain reaction according to manufacturer’s instructions. Briefly, 100 ng of total RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription kit. Pre-amplification was performed by incubating cDNA with a pooled of TaqMan® probes and TaqMan® PreAmp Master Mix for 14 cycles. Quantitative polymerase chain reaction was then carried out in a ViiA7 polymerase chain reaction system. All reagents and kits were purchased from Thermo Fisher Scientific. Results were analyzed with the ΔΔCt method using HPRT expression as a reference for normalization. Details of the probes used in the study are provided in Supplementary Table 1. Protein expression analysis ARVMs protein extracts were obtained using 2% (w/v) sodium dodecyl sulfate solution (Sigma-Aldrich, St. Louis, MO, USA). Equal amounts of protein were subjected to electrophoresis in SDS-polyacrylamide gel under reducing conditions and blotted onto polyvinylidene difluoride membranes (Merck Millipore, Burlington, MA, USA) as previously described35. The membranes were blocked and incubated overnight at 4 °C with the primary antibodies to detect metalloprotease-9 (MMP-9), phospholamban (PLB), phosphorylated PLB (P-PLB; Ser16, Thr17), Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2 (SERCA2), and tissue inhibitor of metalloprotease-1 (TIMP-1). Membranes were then washed with tris-buffered saline and incubated with anti-rabbit or anti-mouse secondary antibodies conjugated to horseradish peroxidase. Immune complexes were detected with the enhanced chemiluminescence ECL detection system (Bio-Rad, Hercules, CA, USA) in a LI-COR C-DiGit® blot scanner (Lincoln, NE, USA) and bands density were analyzed using the LI-COR’s software. The band intensity of SERCA2, MMP-9 and TIMP-1 was normalized to the band intensity of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and then, the ratio MMP-9/TIMP-1 was calculated. P-PLB was normalized to total PLB. Details of the antibodies used in the study are provided in Supplementary Table 2. Statistics and Reproducibility Sample size was determined based on the previously published study on the effects of ART on arterial inflammation and systemic inflammation in persons living with HIV25. These samples were defined as biological replicates since they were derived from different biological sources. For molecular analyses, statistical testing was performed using GraphPad Prism software. Data distribution was assessed using the D’Agostino and Pearson omnibus normality test. The primary comparison was conducted within the same HIV-positive individuals, comparing samples collected pre-ART and on ART. For paired comparisons, a paired Student’s t-test was used for normally distributed data, while the non-parametric Wilcoxon signed-rank test was applied for data that did not follow a normal distribution. When comparing three groups, one-way ANOVA followed by Newman–Keuls post hoc test was used for normally distributed data, and the Kruskal–Wallis test followed by Dunn’s multiple comparisons test was used for non-normally distributed data. Outliers, if any, were determined statistically using a ROUT test. A P-value < 0.050 was considered statistically significant. Results Baseline characteristics of PLWH and control participants Serum from a subset (N = 10) of participants from a prospective clinical study investigating the effects of ART on arterial and systemic inflammation in PLWH cohort25 was used in the current study, and the following are the baseline characteristics. All PLWH were male, predominantly white (80%), with a mean age of 32 ± 10 years. They were normotensive with a mean BMI of 25.6 ± 4.0 kg/m2. The control cohort (persons without HIV and never exposed to ART) was older with a mean age of 52 ± 7 years, predominantly male (70%) and white (80%). The 10-year ASCVD risk score was low and no different between the two groups. Lipid profiles were within normal range, and no PLWH participants were on statin therapy. The median duration of an HIV diagnosis was 0.8 years (0.1, 1.6) in PLWH. Six months on treatment with integrase inhibitor-based ART consisting of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate, 100 % of PLWH achieved an undetectable viral load with a significant improvement in the CD4 + T-cell count vs. baseline from 448 ± 159 cells/μL to 676± 200 cells/μL (P < 0.001) and the CD4 + /CD8+ ratio from 0.54 ± 0.20 to 0.79 ± 0.35 (P < 0.003) (Table 1). RNA sequencing profile in ARVMs treated with serum from PLWH before ART, the same patients six months on ART, and controls A comprehensive evaluation of cardiomyocyte signaling was performed by RNA sequencing from total RNA obtained from ARVMs treated with serum from PLWH followed longitudinally before and on ART for six months, and control subjects (N = 6/group). Details of the analysis are included in the Supplementary Data 1. Cardiomyocyte cell death is increased in ARVMs treated with serum from PLWH before initiation of ART and reduced in ARVM treated with serum from the same individuals after 6 months on therapy Since apoptosis has been reported to play a pathogenic role in HIV-associated cardiomyopathy22,36, we measured DNA fragmentation in ARVMs using TUNEL assays. Treatment with serum collected from PLWH before the initiation of ART significantly increased the proportion of TUNEL-positive ARVMs compared to serum from control subjects (5.62 ± 0.58 % vs. 2.86 ± 0.25 %, P = 0.0001). Serum from the same individuals after being on ART for 6 months resulted in a statistically significant reduction in TUNEL-positive cells (4.22 ± 0.27 %, P = 0.0191; Fig. 1).Fig. 1Cell death and fragmented DNA in ARVMs treated with serum from the same PLWH before ART and after ART, and from persons without HIV (controls, CT).Quantitative analysis of TUNEL-positive cells to the total number of cells [left upper panel, data points represent individuals per sample averages (N = 10 per group)] and representative images (left bottom panel and right panels). Yellow arrows indicate cells with a positive TUNEL signal. Scale bars: 100 μm. Data are mean ± SEM. Statistical analysis: one-way analysis of variance (ANOVA) with Newman-Keuls post hoc test. Cell death and fragmented DNA in ARVMs treated with serum from the same PLWH before ART and after ART, and from persons without HIV (controls, CT). Quantitative analysis of TUNEL-positive cells to the total number of cells [left upper panel, data points represent individuals per sample averages (N = 10 per group)] and representative images (left bottom panel and right panels). Yellow arrows indicate cells with a positive TUNEL signal. Scale bars: 100 μm. Data are mean ± SEM. Statistical analysis: one-way analysis of variance (ANOVA) with Newman-Keuls post hoc test. To investigate potential molecular mechanisms underlying these differences, we performed a systematic gene expression evaluation of the dataset across the three experimental groups. One-way ANOVA analysis identified 13 genes with significantly altered expression (False Discovery Rate corrected p (FDR q) <0.05; Supplementary Table 3), including several genes implicated in genome stability and cellular death, namely immediate early response 3 (Ier3, FDR q = 3.3E-05), O-linked N-acetylglucosamine (GlcNAc) transferase (Ogt, FDR q = 1.9E-03), COMM domain containing 4 (Commd4, FDR q = 1.9E-03), autophagy-related 16-like 2 (Atg16l2, FDR q = 9.3E-03), and dipeptidyl-peptidase 7 (Dpp7, FDR q = 3.7E-02). Cardiomyocyte size is reduced in ARVM treated with serum from PLWH before ART and partially restored with serum from the same individuals after 6 months on therapy Gene expression of Myh6 (α-myosin heavy chain) and Myh7 (β-myosin heavy chain), predominantly expressed in physiological and pathological conditions respectively, were no different between cardiomyocytes treated with serum from persons without HIV (controls), PLWH before ART, and the same PLWH 6 months on ART (Fig. 2A). However, the size of ARVMs was significantly smaller in both PLWH groups regardless of ART status (before ART: 381.0 ± 2.7 μm2, on ART: 397.6 ± 3.1 μm2) compared to controls (417.9 ± 7.6 μm2, P = 0.0001 vs. before ART and P = 0.0077 vs. after ART; Fig. 2B, C). ARVMs treated with serum from PLWH on ART were significantly increased in size compared to those treated with serum from the same ART-naïve participants (P = 0.0252; Fig. 2B, C)Fig. 2Cardiac myocyte size in ARVMs treated with serum from the same PLWH before and after ART, and from persons without HIV (controls, CT).A mRNA relative expression of (α)-myosin heavy chain (Myh6) and β-myosin heavy chain (Myh7) markers. B Cardiomyocyte size. Data points represent individuals per sample average (N = 10). C Representative images. Scale bars: 100 μm. Data are mean ± SEM. N = 8–10/group. Statistical analysis: one-way analysis of variance (ANOVA) with Newman-Keuls post hoc test. Cardiac myocyte size in ARVMs treated with serum from the same PLWH before and after ART, and from persons without HIV (controls, CT). A mRNA relative expression of (α)-myosin heavy chain (Myh6) and β-myosin heavy chain (Myh7) markers. B Cardiomyocyte size. Data points represent individuals per sample average (N = 10). C Representative images. Scale bars: 100 μm. Data are mean ± SEM. N = 8–10/group. Statistical analysis: one-way analysis of variance (ANOVA) with Newman-Keuls post hoc test. Pathway enrichment analysis in ARVMs after treatment with serum from the same PLWH followed before and 6 months on ART To determine if differences in molecular signatures occurred between cardiomyocytes treated with serum from PLWH before and on ART, pathway enrichment analyses of the sequencing dataset were performed (Supplementary Data 2). This permitted examination of biological pathways or processes between the two experimental groups that were either concordantly upregulated or downregulated in databases of molecular signatures, as previously reported37. Two hundred and eighty-one pathways/processes were markedly different between cardiomyocytes treated with serum from PLWH before and on ART (FDR q < 0.05). Of these, 262 were upregulated and 19 downregulated in post-ART vs. pre-ART. Serum from PLWH on ART for 6 months causes downregulation of cardiac conduction and contraction pathways in cardiomyocytes GSEA demonstrated a coordinate downregulation of gene sets related to cardiac conduction and contraction in ARVMs treated with serum from PLWH post-ART vs. the same PLWH pre-ART. Of the total 19 significant downregulated pathways, seven were related to cardiac conduction and contraction (Supplementary Table 4). A heatmap of the union set of leading-edge genes from three selected gene sets is shown in Fig. 3.Fig. 3Heatmap of the union set of leading-edge genes from 3 selected gene sets related to cardiac conduction and contraction.The expression of the leading-edge genes is shown across the same subjects before ART and after ART (i.e., 6 months on ART). Columns and rows correspond to genes and samples, respectively. Expression values were scaled by first subtracting the mean expression of each subject (across both time points) and then z-normalizing the subject-adjusted expression values to a mean of zero and standard deviation of 1 across all samples in each row. Red, white, and blue indicate z-scores of ≥2, 0, and ≤2, respectively. Columns (genes) are placed in descending order from left to right by the strength of the paired Wald statistic used to rank genes for GSEA. Heatmap of the union set of leading-edge genes from 3 selected gene sets related to cardiac conduction and contraction. The expression of the leading-edge genes is shown across the same subjects before ART and after ART (i.e., 6 months on ART). Columns and rows correspond to genes and samples, respectively. Expression values were scaled by first subtracting the mean expression of each subject (across both time points) and then z-normalizing the subject-adjusted expression values to a mean of zero and standard deviation of 1 across all samples in each row. Red, white, and blue indicate z-scores of ≥2, 0, and ≤2, respectively. Columns (genes) are placed in descending order from left to right by the strength of the paired Wald statistic used to rank genes for GSEA. Changes in calcium handling proteins in ARVMs treated with serum from the same PLWH before and on ART During LV diastolic dysfunction, which is evident in PLWH, intracellular diastolic calcium handling is abnormal and regulated by the calcium-handling proteins SERCA2 and its modulator PLB38. We therefore sought to further investigate the GSEA findings of altered calcium mobilization, contraction and relaxation, and measured protein expression of SERCA2 and PLB as previously shown39 (Fig. 4A). SERCA2 protein expression was comparable between ARVMs treated with serum from PLWH before ART vs. on ART (Fig. 4B). Phosphorylation of PLB was reduced in ARVMs treated with serum from PLWH on ART vs. ARVMs treated with serum from the same participants pre-ART (1.15 ± 0.05 vs. 1.39 ± 0.13, P < 0.0410; Fig. 4C). However, the ratio of PLB and SERCA2 protein expression was no different between the groups (Fig. 4D).Fig. 4Calcium-handling proteins expression in ARVMs treated with serum from the same PLWH before ART and after ART.A Cartoon schema to illustrate the role of sarcoendoplasmic reticulum Ca2+ ATPase 2 (SERCA2) and phospholamban (PLB) in regulating cardiac cell contraction. This figure was partly generated using Biorender.com. B SERCA2 protein relative expression and representative blots. C Phosphorylation of PLB at serine 16 and threonine 17 and total PLB protein relative expression and representative blots. D Ratio of total PLB to SERCA2 protein relative expression. N = 8/group. Data are mean ± SEM. Statistical analysis: Wilcoxon matched-pairs signed rank test (B) and one-tailed paired T test (C,D). Calcium-handling proteins expression in ARVMs treated with serum from the same PLWH before ART and after ART. A Cartoon schema to illustrate the role of sarcoendoplasmic reticulum Ca2+ ATPase 2 (SERCA2) and phospholamban (PLB) in regulating cardiac cell contraction. This figure was partly generated using Biorender.com. B SERCA2 protein relative expression and representative blots. C Phosphorylation of PLB at serine 16 and threonine 17 and total PLB protein relative expression and representative blots. D Ratio of total PLB to SERCA2 protein relative expression. N = 8/group. Data are mean ± SEM. Statistical analysis: Wilcoxon matched-pairs signed rank test (B) and one-tailed paired T test (C,D). Serum from PLWH on ART for 6 months increases extracellular matrix (ECM) remodeling gene sets and alters the expression of fibrotic markers in cardiomyocytes Of the 262 GSEA upregulated pathways, there was a significant coordinated upregulation of several gene sets associated with ECM remodeling, including the GOMF_EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT, the REACTOME_COLLAGEN_FORMATION, and the REACTOME_ASSEMBLY_OF_COLLAGEN_FIBRILS in ARVMs treated with serum from PLWH after 6 months of ART vs. those treated with serum from the same participants before ART initiation (Supplementary Table 5). This reflects changes in ECM remodeling activity and fibrosis-related processes after treatment with ART. A heatmap of the union set of leading-edge genes from five of these gene sets is shown in Fig. 5.Fig. 5Heatmap of the union set of leading-edge genes from 5 selected gene sets related to collagen turnover, extracellular matrix, and cardiac remodeling.The expression of the leading-edge genes is shown across the same PLWH before ART and after ART (i.e., 6 months on ART). Columns and rows correspond to genes and samples, respectively. Expression values were scaled by subtracting the mean expression of each subject (across both time points) and z-normalizing the subject-adjusted expression values to a mean of zero and standard deviation of 1 across all samples in each row. Red, white, and blue indicate z-scores of ≥2, 0, and ≤2, respectively. Columns (genes) are placed in descending order from left to right by the strength of the paired Wald statistic used to rank genes for GSEA. Heatmap of the union set of leading-edge genes from 5 selected gene sets related to collagen turnover, extracellular matrix, and cardiac remodeling. The expression of the leading-edge genes is shown across the same PLWH before ART and after ART (i.e., 6 months on ART). Columns and rows correspond to genes and samples, respectively. Expression values were scaled by subtracting the mean expression of each subject (across both time points) and z-normalizing the subject-adjusted expression values to a mean of zero and standard deviation of 1 across all samples in each row. Red, white, and blue indicate z-scores of ≥2, 0, and ≤2, respectively. Columns (genes) are placed in descending order from left to right by the strength of the paired Wald statistic used to rank genes for GSEA. To further investigate these findings, the expression of selected cardiac-relevant fibrotic markers found across the GSEA gene sets, including galectin-3 (Lgals3), lysyl oxidase (Lox), lox-like 1 (Loxl1), MMP-9, and TIMP-1 was measured (Fig. 6A). Lgals3 and Loxl1 mRNA expression were significantly increased in ARVMs treated with serum from PLWH on ART vs. the same participants pre-ART (1.27 ± 0.23 vs. 0.82 ± 0.12, P = 0.0237; and 0.93 ± 0.21 vs. 0.71 ± 0.19, P = 0.0078, respectively). However, lox mRNA expression was no different between groups (Fig. 6B). The ratio of MMP-9/TIMP-1 protein expression was also determined and showed a significant increase in ARVMs treated with serum from PLWH on ART treatment vs. before ART (0.72 ± 0.14 vs. 0.48 ± 0.10, P = 0.0384; Fig. 6C).Fig. 6Cardiac remodeling markers in ARVMs treated with serum from the same PLWH before ART and after ART.A Cartoon schema to illustrate the role of galectin-3 (Lgals3), lysyl oxidase (Lox), lox like 1 (Loxl1), matrix metallopeptidase 9 (MMP-9), and tissue inhibitor of metalloprotease 1 (TIMP-1) in cardiac remodeling. This figure was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license. B Relative Lgals3, Lox, and Loxl1 mRNA expression. C Ratio of MMP-9 to TIMP-1 protein expression with representative immunoblots. N = 8/group. Data are mean ± SEM. Statistical analysis: Wilcoxon matched-pairs signed rank test for Loxl1 and one-tailed paired T test for the rest. Cardiac remodeling markers in ARVMs treated with serum from the same PLWH before ART and after ART. A Cartoon schema to illustrate the role of galectin-3 (Lgals3), lysyl oxidase (Lox), lox like 1 (Loxl1), matrix metallopeptidase 9 (MMP-9), and tissue inhibitor of metalloprotease 1 (TIMP-1) in cardiac remodeling. This figure was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license. B Relative Lgals3, Lox, and Loxl1 mRNA expression. C Ratio of MMP-9 to TIMP-1 protein expression with representative immunoblots. N = 8/group. Data are mean ± SEM. Statistical analysis: Wilcoxon matched-pairs signed rank test for Loxl1 and one-tailed paired T test for the rest. Discussion ART has substantially reduced the incidence of AIDS-related complications; however, cardiovascular conditions, such as HFpEF are becoming increasingly prevalent in PLWH despite effective ART use4,10. Cardiometabolic traits seen with some ART regimens, such as dyslipidemia, obesity, diabetes, or CAD, may play a key role in mediating the development of LV diastolic dysfunction and HFpEF in PLWH15. However, the specific mechanisms behind those comorbidities are unknown. While LV diastolic dysfunction and HFpEF are touted to be due to increasing metabolic complications, the present study indicates that the direct effects on cardiomyocytes are due to ART, as PLWH included in the study were at an overall low risk for cardiovascular events, and with very limited traditional CAD risk factors. Cardiomyocyte loss and replacement by immune cells and fibrous tissue are known to occur in HIV-associated cardiomyopathy40. Apoptosis is a major form of cardiomyocyte death in HIV-associated cardiomyopathy22,36. Thus, apoptotic cell death was investigated in cardiomyocytes treated with serum from PLWH before and on ART. Apoptosis was increased in cardiomyocytes treated with serum from ART-naïve PLWH, and subsequently decreased in those treated with serum from the same participants on ART. Interestingly, these results were further supported by evidence of cell shrinkage, a key feature of apoptosis41. This suggests that circulating factors in the serum of untreated PLWH promote apoptotic death, but identifying the specific factors is beyond the scope of the current study. Despite cardiomyocytes not expressing CD4 receptors19,36, certain HIV proteins, such as glycoprotein 120 (GP120), may induce cellular apoptosis22 by binding to the co-receptors C-C chemokine receptor 5 (CCR5) or C-X-C chemokine receptor (CXCR4), both expressed in cardiomyocytes42,43 and shown to activate apoptotic pathways36,42,43. Subclinical cardiac abnormalities, including impaired LV diastolic function and cardiac strain patterns, are frequently observed in PLWH on ART44. These are the results of anatomical or organ-level abnormalities leading to abnormal relaxation and delayed LV ventricular filling. However structural, molecular, and biochemical changes also play an important role within the cardiomyocytes45. GSEA findings revealed marked changes in biological pathways related to calcium handling in cardiomyocytes, which were predominantly downregulated after treatment with serum from PLWH on ART. Calcium storage and transport by SERCA2 play a crucial role in regulating cardiac contraction and relaxation. Its activity is determined by the ratio of PLB to SERCA2 expression and the phosphorylation status of PLB46. Decreased phosphorylation of PLB or an increased PLB/SERCA2 ratio are both associated with impaired LV relaxation and contraction and may manifest as impaired LV diastolic function39,47. In this study, despite the lack of changes in SERCA2 expression or the PLB/SERCA2 ratio between the PLWH groups, PLB phosphorylation was reduced in cardiomyocytes treated with serum from PLWH on ART vs. pre-ART, indicating that ART may have a direct effect on the contractile function of cardiomyocytes. There is limited information on the effect of ART on calcium handling proteins and calcium cycling in cardiomyocytes. The impact of integrase inhibitor-based ART (like the current regimen in this study) has not previously been explored. In AIDS transgenic mice infected with replication-incompetent HIV-1 and treated with zidovudine, a nucleoside reverse transcriptase inhibitor, SERCA2 levels were decreased, with minimal changes in cardiac relaxation48, while treatment with a chronic combination of the protease inhibitors lopinavir and ritonavir in Wistar rats increased SERCA2 expression49 and PLB phosphorylation50. Here, we hypothesize that ART may indirectly reduce PLB phosphorylation by altering upstream signaling pathways that regulate protein kinase A (PKA) or Ca²⁺/calmodulin-dependent protein kinase II (CaMKII), both of which mediate PLB phosphorylation51. Alternatively, ART may enhance the activity of protein phosphatase 1 (PP1), the primary phosphatase responsible for PLB dephosphorylation52, potentially through changes in circulating factors, such as inflammatory cytokines, oxidative stress markers, or adipokines, factors known to influence the kinase/phosphatase balance in cardiomyocytes53,54. Therefore, further mechanistic studies are needed to investigate the differential effects of specific ART regimens on calcium-handling proteins and LV diastolic function, and to determine whether these effects are directly attributable to ART or secondary to systemic immune restoration and metabolic shifts following viral suppression. Moreover, while our findings suggest a potential link between ART exposure and impaired calcium handling in cardiomyocytes, additional studies are warranted to clarify the structural and functional consequences of these molecular changes. Specifically, studies employing advanced techniques, such as high-resolution imaging to assess alterations in cardiomyocyte architecture and direct measurements of contractile function, will be essential to understanding how disruptions in calcium-handling pathways impact overall cell physiology. Accelerated myocardial fibrosis also likely participates in the phenotype of HIV-related impaired LV diastolic function55. In asymptomatic ART-treated PLWH with complete viremia suppression, cardiac MRI studies still demonstrated diffuse and focal myocardial fibrosis56. In the Characterization of Heart Function on Antiretroviral Therapy (CHART) study, ART-treated PLWH demonstrated focal myocardial fibrosis and higher circulating levels of carboxyl-terminal telopeptide of collagen type I in the setting of LV diastolic dysfunction, altered cardiac structure, and worse quality-of-life scores, suggesting a pathogenic role of adverse cardiac remodeling and fibrosis57. However, the exact mechanisms by which PLWH on ART present with increased cardiac fibrosis are not fully understood. In our study, biological pathways related to cardiac fibrosis were upregulated in cardiomyocytes treated with serum from PLWH receiving ART. Although activated fibroblasts and myofibroblasts are essential cellular effectors in cardiac fibrosis, other cell types, such as immune cells, endothelial cells, and cardiomyocytes, also contribute to ECM remodeling58. Cardiomyocytes and fibroblasts display bidirectional crosstalk in the heart and communicate via paracrine factors, cell-to-cell, and ECM interactions59,60. In this study, cardiomyocytes exposed to serum from PLWH on ART demonstrated increased galectin-3 and Loxl1 transcript levels compared to those treated with serum from newly diagnosed, pre-ART PLWH. Galectin-3 stimulates ECM production and myofibroblast activation61. Loxl1 expression is increased in pathological conditions and is a major enzyme required for cross-link formation of collagen fibrils62. These increases were also accompanied by changes in the ratio of MMP-9 to TIMP-1, suggesting an important function of cardiomyocytes in mediating ECM remodeling and cardiac fibrosis in response to ART. Several limitations should be considered when interpreting the findings of this study. (1) There were no women in this small PLWH cohort who were recruited from an HIV clinic. Although the longitudinal study design, using paired serum samples from the same individuals’ pre-ART and on ART, helped mitigate the limitation of a modest sample size, future studies must include women to validate and extend these findings. The control population was older; however, the key comparisons in this study were not between controls and PLWH, but rather between serum from the same PLWH before versus after ART initiation, which is a primary strength of the design. (2) There are species differences between rats and humans, but it is well supported that ARVM fully recapitulate the human adult cardiac myocyte phenotype, with respect to function, gene and protein expression, metabolism, and electrical properties63,64. In contrast, human pluripotent stem cell–derived cardiomyocytes exhibit substantial variability, depend heavily on cell source, and remain structurally and functionally immature, retaining a fetal phenotype with markedly different characteristics from mature cardiomyocytes, which has contributed to poor in vivo translation. (3) Finally, the study used a single standardized ART regimen across all PLWH participants, limiting generalizability to other ART combinations. Although all individuals received INSTI-based therapy, the study was not designed to investigate differences between ART classes. Future studies will be necessary to distinguish the direct effects of ART drugs from immunologic changes associated with viral suppression on the cardiomyocyte phenotype. One potential approach is to treat cardiomyocytes with serum from individuals on PrEP (pre-exposure prophylaxis), which is taken by HIV-negative individuals to prevent HIV acquisition. This approach may help distinguish ART-specific effects from those related to HIV infection or immune activation. Additional research is also warranted to examine the cardiovascular effects of diverse ART regimens, as different combinations may exert unique influences on cardiomyocyte function and extracellular matrix remodeling. In conclusion, this study demonstrates a distinct molecular signature in cardiomyocytes treated with serum from PLWH on ART compared with serum obtained from the same participants prior to ART initiation. Primary ARVM were treated with matched serum samples collected from newly diagnosed, ART-naïve PLWH and again from the same individuals six months after starting ART. The initial study by Zanni et al. reported significant improvements in systemic immune biomarkers after six months of combined ART25. The major findings of this ancillary study include: (i) increased cardiomyocyte cell death when treated with pre-ART serum, but reduced cell death when treated with post-ART serum; (ii) alterations in calcium-handling proteins indicative of impaired cardiomyocyte relaxation on ART compared with pre-ART; and (iii) increased markers of adverse ECM remodeling in cardiomyocytes exposed to post-ART serum compared with pre-ART. These results support the presence of distinct, HIV- and ART-responsive signaling pathways in cardiomyocytes. Such molecular signatures may precede the development of HFpEF characterized by impaired LV diastolic function in PLWH. However, the exact circulating mediators responsible for these effects remain undefined. HIV infection, including during effective viral suppression, is characterized by chronic immune activation, persistent inflammation25, and extensive dysregulation of the plasma proteome, metabolome, and lipidome65,66, all of which may affect cardiomyocyte function and contribute to systemic inflammation and cardiometabolic complications25,67. Further studies are warranted to determine whether modulating these cardiomyocyte signatures can mitigate progression toward HFpEF with LV diastolic dysfunction in PLWH. Supplementary information Transparent Peer Review file SUPPLEMENTAL MATERIAL Description of Additional Supplementary files Supplementary Data 1 Supplementary Data 2 Supplementary Data 3 Transparent Peer Review file SUPPLEMENTAL MATERIAL Description of Additional Supplementary files Supplementary Data 1 Supplementary Data 2 Supplementary Data 3